Hearing loss company Acousia Therapeutics presenting at upcoming drug development and B2B conferences

The senior management of Acousia Therapeutics GmbH will be discussing the company’s approach to translational development of small molecule drug candidates for the treatment of hearing loss at the upcoming Inner Ear Disorders Therapeutics Summit (May 25–27, 2021) and the Bellucci Symposium on Hearing Research (June 3–4, 2021). Furthermore, the company will be presenting and engaging in partnering discussions at the European Bio€quity Meeting (May 17–21).

„We are advancing rapidly towards clinical testing of our first development candidate ACOU085 in patients with age-related hearing loss,” said CEO Tim Bölke.

Professor Hubert Löwenheim, chair of the Tübingen University ENT clinic and Acousia Therapeutics co-founder added: „Despite the overwhelming burden of hearing loss for patients and society, the quest for drug therapies against hearing loss remains one of the most under-resourced areas in drug discovery.”

„The heterogeneity of etiologies and lack of standards for drug development in the field present an exciting challenge in delivering novel solutions for patients suffering from hearing loss,” said Chief Development Officer Jonas Dyhrfjeld-Johnsen. „We believe that a robust understanding of the hearing-loss pathophysiology combined with solid translational principles opens the door to preserving and enhancing the natural hearing of patients in an individualized/personalized manner.”

Acousia Therapeutics GmbH is developing a series of small molecule drug candidates for local and systemic treatment of different forms of hearing loss. While the start of the ACOU085 phase 1 study in patients with age-related hearing loss is planned for the second half of 2021, next generation drug candidates are being thoroughly characterized in a range of both specialized and standard preclinical models and assays.

Share this release

Share on facebook
Share on twitter
Share on linkedin
Share on xing
Share on email
Latest news

Tim Boelke, M.D.

About Acousia Therapeutics GmbH

Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. The unique dual mode of action of its small-molecule Kv7.4 activators combines acute functional OHC enhancement and sustained OHC protection and aims to both enhance and preserve a patient’s natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.